Research from the University of California, Irvine has revealed how disruption of the circadian clock, the body’s internal, 24-hour biological pacemaker, may accelerate the progression of colorectal cancer by affecting the gut microbiome and intestinal barrier function.
AbbVie’s Q2 2024 net earnings drop to $1.37bn
AbbVie’s adjusted diluted EPS stood at $2.65 compared to $2.91bn in Q2 2023, reflecting an 8.9% decrease. Credit: JRdes / Shutterstock. AbbVie has announced its
July 26, 2024